Results 51 to 60 of about 75,203 (286)

Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia

, 2016
Full author list omitted for brevity. For full list of authors see article.Heavy drinkers are at risk for a spectrum of histologic alcohol-related liver injury: steatosis, alcoholic steatohepatitis (ASH), alcohol-related fibrosis, and cirrhosis ...
Szabo, Gyongyi, NIAAA Alcoholic Hepatitis Consortia, Crabb, David W.   +2 more
core   +1 more source

Attacking the public health crisis of hepatocellular carcinoma at its roots

Hepatology, EarlyView., 2022
Abstract As the third most common cause of cancer‐related death worldwide with significant mortality rates in the United States, hepatocellular carcinoma has strong association with cirrhosis and chronic hepatitis B virus (HBV) with a growing at‐risk population from the rise in chronic liver disease from alcohol use and nonalcoholic fatty liver disease.
Hannah M. Lee, Steven D. Lidofsky, Tamar H. Taddei, Lisa J. Townshend‐Bulson   +3 more
wiley   +1 more source

Hepatitis C and alcohol [PDF]

Hepatology, 1997
Chronic alcoholism in patients with chronic hepatitis C appears to cause more severe and rapidly progressive liver disease leading more frequently to cirrhosis of the liver and hepatocellular carcinoma. The primary risk factor for acquiring hepatitis C among alcoholics is injection drug use.
openaire   +2 more sources

A novel mortality model for acute alcoholic hepatitis including variables recorded after admission to hospital

, 2014
Severe forms of alcoholic hepatitis in patients with alcoholic liver disease are associated with high mortality; it is therefore vital to identify those patients at greatest risk of mortality in 28 days as they may benefit from aggressive intervention ...
Hussain, Amir, Hussain, Sajid, Shah, Amir A., Mazzocco, Thomas   +3 more
core   +1 more source

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Machine Learning Applied to Omics Datasets Predicts Mortality in Patients with Alcoholic Hepatitis

Metabolites, 2022
Alcoholic hepatitis is a major health care burden in the United States due to significant morbidity and mortality. Early identification of patients with alcoholic hepatitis at greatest risk of death is extremely important for proper treatments and ...
Bei Gao, Tsung-Chin Wu, Sonja Lang, Lu Jiang, Yi Duan, Derrick E. Fouts, Xinlian Zhang, Xin-Ming Tu, Bernd Schnabl   +8 more
doaj   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Acute Alcoholic Hepatitis

Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2017
Objective: To examine the natural history of acute alcoholic hepatitis (AH) and identify predictors of mortality for AH using data from a prospective multicenter observational study.
Spencer Lourens, PhD, Dharma B. Sunjaya, MD, Ashwani Singal, MD, Suthat Liangpunsakul, MD, MPH, Puneet Puri, MD, Arun Sanyal, MD, Xiaowei Ren, MS, Gregory J. Gores, MD, Svetlana Radaeva, PhD, Naga Chalasani, MD, David W. Crabb, MD, Barry Katz, PhD, Patrick S. Kamath, MD, Vijay H. Shah, MD, David Crabb, MD, Naga Chalasani, MD, Suthat Liangpunsakul, MD, Barry Katz, PhD, Spencer Lourens, PhD, Andy Borst, BS, Ryan Cook, MPH, Andy Qigui Yu, PhD, David Nelson, PhD, Romil Saxena, MD, Sherrie Cummings, RN, Megan Comerford, BS, Lakye Edwards, BS, Vijay H. Shah, MD, Gregory Gores, MD, Patrick S. Kamath, MD, Vikas Verma, PhD, Sarah Wilder, RN, BSN, Amy Olofson, RN, Amanda Schimek, Arun Sanyal, MD, Puneet Puri, MD, Susan Walker, RN, MSN, Svetlana Radaeva, PhD, Andras Orosz, PhD   +38 more
doaj   +1 more source

Specificities of lipotoxicity of free fatty acids and cytokine profile in patients with chronic diffuse liver diseases

Regulatory Mechanisms in Biosystems, 2021
Non-alcoholic fatty liver disease is an important cause of global liver disease characterized by diffuse hepatocytes with hepatocellular ballooning, intrahepatic inflammation and progressive fibrosis.
V. I. Didenko, I. A. Klenina, О. M. Tatarchuk, O. I. Hrabovska, O. P. Petishko   +4 more
doaj   +1 more source